Glaxo Studies Three-In-One Emphysema Medicine to Keep Lead – Businessweek

Glaxo Studies Three-In-One Emphysema Medicine to Keep Lead
Businessweek
GlaxoSmithKline Plc (GSK), maker of Advair, the world's best-selling drug for smoker's cough and asthma, is considering a three-in-one treatment delivered in a single device to stay ahead of competitors such as Novartis AG. Patients taking 400

and more »

View full post on world asthma day – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *